Navigation Links
Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
Date:12/1/2011

WORCESTER, Mass. and TORONTO, Dec. 1, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today provided an update on the status of the clinical and regulatory program for Generex Oral-lyn™, the Company's proprietary buccal insulin spray product.

Work has been completed on reviewing, validating, re-analyzing (including additional new analyses), and revising all of the extant Generex Oral-lyn™ Clinical Study Reports.  In addition, the data collection, analysis, review, and preparation of the final Clinical Study Report for the recently concluded Generex Oral-lyn™ Study 084, A 26-Week, Open-Label, Randomized, Active Comparator Study of Generex Oral-lyn™ Spray and Injected Human Insulin In Subjects With Type 1 Diabetes Mellitus, has been completed.

This will allow an on-schedule completion this quarter of Generex's response to USFDA queries (as described during the annual meeting of stockholders in June).  The new Generex Oral-lyn™ Investigators' Brochure (required for review and conduct of future Generex Oral-lyn™ studies) remains on schedule for completion, submission to the regulatory agencies of all countries participating in Generex Oral-lyn™ trials, and publication for investigators and ethical review boards in the first quarter of 2012.

The new clinical development plan, including pharmacokinetic and gluco-dynamic studies, a comprehensive clinical phase 3 program (to assure appropriate marketing approval to treat every type of patient with diabetes), and a small number of well-designed physiologic studies to demonstrate the unique advantages of Generex Oral-lyn™ (vital for marketing and reimbursement) will be announced early in the first quarter of 2012.  Additionally, a meeting with the USFDA will be scheduled in the first quarter to insure consensus with the clinical plan to help achieve an e
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting
2. Generex Provides Update on Spinout of Antigen Express
3. Generex Augments Cash Position With Sales of Non-Essential Assets
4. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
5. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
6. Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America
7. Generex Provides Clarification of Facts
8. Generex Announces Results of Annual Stockholders Meeting
9. Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
10. Generex Oral-lyn™ Data to be Presented at Two International Scientific Symposia
11. Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... -- Guggenheim Securities, the investment banking and capital markets ... veteran equity analyst Charles "Tony" Butler as a managing ... on the biotech/biopharma sector. " Tony Butler ... a broad network of relationships in his industry," said ... of Equities at Guggenheim Securities. "His insights will further ...
(Date:8/27/2014)... 27, 2014  ARCH Venture Partners, one of ... the development of seed and early-stage advanced technology ... closed with more than $400 million in subscriptions. ... subscription target by more than $150 million. ... strength and potential of our approach to finding ...
(Date:8/27/2014)... City, OR (PRWEB) August 27, 2014 ... Report, “Consolidation continues to reshape the look and feel ... nutrition. Consumer demand for higher-quality ingredients will push for ... North American market have experienced strong market growth in ... ethical attributes in their food and cosmetics to fit ...
(Date:8/26/2014)... -- NeuroSigma, Inc., a Los Angeles -based ... announced that it has filed a registration statement on ... relating to a proposed initial public offering of its ... and the price range for the proposed offering have ... act as the book-running manager for the proposed offering, ...
Breaking Biology Technology:Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3
... , , NEW YORK, Aug. 13 ... the second quarter ended June 30, 2009. , , Revenues ... in 2008. Net loss for the second quarter of 2009 was $103,330, ... Basic net loss per share for the second quarter of 2009 was $0.01, ...
... , , MANHATTAN, ... around the world hundreds of millions of dollars each year. , ... Hesse and Bob Rowland have been working to create new vaccines ... and its associated diseases continue to emerge around the world," Hesse ...
... FORT LAUDERDALE, Fla., Aug. 13 OmniComm Systems, Inc. ... capture (EDC) solutions for clinical trials, today announced that it ... Organization (CRO) to provide eClinical solutions for a pivotal Phase ... serve to establish the safety and efficacy of investigational new ...
Cached Biology Technology:Cadus Reports Second Quarter 2009 Results 2Cadus Reports Second Quarter 2009 Results 3Cadus Reports Second Quarter 2009 Results 4Cadus Reports Second Quarter 2009 Results 5K-State's Biosecurity Research Institute Gives Researchers the Tools Needed to Study Diseases That Cost Pig Producers Hundreds of Millions of Dollars Each Year 2K-State's Biosecurity Research Institute Gives Researchers the Tools Needed to Study Diseases That Cost Pig Producers Hundreds of Millions of Dollars Each Year 3Leading European Contract Research Organization Selects OmniComm to Provide eClinical Solutions for Important Phase III Study 2
(Date:8/27/2014)... that a deficiency in serotonin a chemical messenger ... depression. In the journal ACS Chemical Neuroscience , ... serotonin in their brains (and thus should have been ... , Donald Kuhn and colleagues at the John ... School of Medicine note that depression poses a major ...
(Date:8/27/2014)... have largely succeeded in sidelining the use of ... its potential contributions to Americans, health conditions. But ... best way to assuage the nation,s insatiable sweet ... & Engineering News (C&EN), the weekly news ... the article, Stephen Ritter, a senior correspondent at ...
(Date:8/27/2014)... can be weaned later with no negative effects on ... at the University,s Roseworthy campus, published in the journal ... for pig producers. It allows improvements in piglet health ... usually start their oestrous cycles again during lactation, only ... says Ms Alice Weaver, PhD candidate with the School ...
Breaking Biology News(10 mins):New study throws into question long-held belief about depression 2Piglet weaning age no bar to litter frequency 2
... identify new anti-cancer, anti-infection response control mechanism , ... de recherches cliniques de Montréal (IRCM), and his ... the prestigious journal Nature Immunology of Nature Publishing ... treatment of cancers and infectious diseases. Current treatments ...
... to clone human embryos from eggs that have been ... easier for scientists to create embryonic stem cell lines ... and sperm for infertile couples, the 21st annual conference ... heard today (Monday 20 June). , Until now, scientists ...
... the structure of a crucial human immune system molecule ... an upcoming issue of the journal Science, the protein ... 23 leucine-rich repeats (LRRs). , The structure reveals details ... essential step toward fully understanding the critical role this ...
Cached Biology News:Major breakthrough in the treatment of cancers and infectious diseases 2Scientists succeed in cloning human embryos from eggs matured in the lab 2Scientists succeed in cloning human embryos from eggs matured in the lab 3Scripps research scientists solve structure of a critical innate immune system protein 2Scripps research scientists solve structure of a critical innate immune system protein 3Scripps research scientists solve structure of a critical innate immune system protein 4